Movva N, Bylsma L, Suh M, Kelsh M, Van Valkenburgh H, Zaha R. 2025. Systematic literature review of bioavailability of characteristics, clinical presentations, and outcomes among women with pregnancies affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) and/or have anti-HPA-1a antibodies with no history of FNAIT. PROSPERO 2025:CRD420251153257. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251153257.
Abstract
The condition being studied is FNAIT, which is a rare condition that stems from maternal alloimmunization against HPA. The HPA-1 antigen is involved in the majority of FNAIT cases. This condition can lead to intracranial hemorrhage (ICH) which can result in subsequent long-term health issues such as developmental delays and disabilities. There is no routine screening for FNAIT during pregnancy and typically, diagnosis is made after the mother gives birth. Various treatment options are available based on the timing of diagnosis but there are no therapies that prevent the development of FNAIT. Review objectives: What are the clinical presentations, outcomes, and characteristics of women who have been affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) or have antibodies against human platelet antigen-1a (HPA-1a) with no history of FNAIT?